Oxford Biodynamics jumps on interim findings from ongoing CiRT trial
By Josh White
Date: Thursday 04 Sep 2025
(Sharecast News) - Oxford BioDynamics said on Thursday that interim results from its ongoing FDA-registered PROWES trial demonstrated that its EpiSwitch CiRT test had a significant impact on treatment decisions for cancer patients receiving immune checkpoint inhibitors.
The AIM-traded firm said the peer-reviewed study, published in the journal Cancers, assessed 205 patients across a range of advanced solid tumours.
It said CiRT, a blood test that predicts a patient's likely response to checkpoint inhibitors, showed sensitivity of 93%, specificity of 82% and accuracy of 85%.
The company said the test influenced oncologists' treatment choices in 61% of cases, including decisions to start, escalate, de-escalate or avoid therapy.
Among patients with a 'Low Probability of Response' result, nearly half avoided ineffective treatment, reducing exposure to potentially serious side effects, while almost three-quarters of patients with a 'High Probability of Response' had their therapy continued or escalated.
The results also closely matched real-world outcomes and were consistent across race, ethnicity, socioeconomic status, and treatment setting.
"The PROWES results represent a significant milestone that further validates the transformative real-world impact of the EpiSwitch CiRT test on decision-making in real clinical practice," said Thomas Guiel, chief operating officer at Oxford BioDynamics.
"These results not only strengthen the scientific foundation of CiRT, but also support our strategy to secure inclusion in NCCN (National Comprehensive Cancer Network) clinical guidelines."
The firm said it planned to apply for inclusion in the US NCCN guidelines later in the year, which it described as a critical step towards broader adoption.
Unlike invasive tissue-based diagnostics such as PD-L1 expression or genetic testing, OBD said CiRT uses a blood sample to deliver a minimally invasive result based on a patient's immune system readiness.
Oxford BioDynamics added that the test's ability to prevent unnecessary use of immune checkpoint inhibitors, which could cost more than $850,000 per patient with supportive care, could deliver major cost savings.
CiRT was already available privately in the UK, covered by Bupa, and in the US under a unique PLA reimbursement code.
At 1144 BST, shares in Oxford BioDynamics were up 15.49% at 0.52p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN